Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma.
Perret A, Dômont J, Chamseddine AN, Dumont SN, Verret B, Briand S, Court C, Lazure T, Adam J, Ngo C, Even C, Levy A, Bayle A, Lucibello F, Haddag-Miliani L, Faron M, Honoré C, Le Cesne A, Mir O. Perret A, et al. Among authors: bayle a. Cancer Med. 2021 Jan;10(1):230-236. doi: 10.1002/cam4.3610. Epub 2020 Nov 25. Cancer Med. 2021. PMID: 33236839 Free PMC article.
Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status.
Mir O, Honoré C, Chamseddine AN, Dômont J, Dumont SN, Cavalcanti A, Faron M, Rimareix F, Haddag-Miliani L, Le Péchoux C, Levy A, Court C, Briand S, Fadel E, Mercier O, Bayle A, Brunet A, Ngo C, Rouleau E, Adam J, Le Cesne A. Mir O, et al. Among authors: bayle a. Clin Cancer Res. 2020 Dec 1;26(23):6277-6283. doi: 10.1158/1078-0432.CCR-20-1847. Epub 2020 Sep 1. Clin Cancer Res. 2020. PMID: 32873570
Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks.
Bayle A, Hollebecque A, Pistilli B, Massard C, Marabelle A. Bayle A, et al. Eur J Cancer. 2021 Oct;156:217-221. doi: 10.1016/j.ejca.2021.06.044. Epub 2021 Aug 14. Eur J Cancer. 2021. PMID: 34400059 No abstract available.
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.
Albiges L, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, Stoclin A, Merad M, Griscelli F, Lacroix L, Netzer F, Hueso T, Balleyguier C, Ammari S, Colomba E, Baciarello G, Perret A, Hollebecque A, Hadoux J, Michot JM, Chaput N, Saada V, Hauchecorne M, Micol JB, Sun R, Valteau-Couanet D, André F, Scotte F, Besse B, Soria JC, Barlesi F. Albiges L, et al. Among authors: bayle a. Nat Cancer. 2020 Oct;1(10):965-975. doi: 10.1038/s43018-020-00120-5. Epub 2020 Sep 22. Nat Cancer. 2020. PMID: 35121871
Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas.
Blanchi J, Taleb S, Bayle A, Verret B, Toulmonde M, Spalato-Ceruso M, Dubos P, Laizet Y, Alame M, Khalifa E, Italiano A. Blanchi J, et al. Among authors: bayle a. Cancer Commun (Lond). 2023 Sep;43(9):1051-1054. doi: 10.1002/cac2.12461. Epub 2023 Jul 5. Cancer Commun (Lond). 2023. PMID: 37405935 Free PMC article. No abstract available.
75 results